OncoMed Announces First Quarter 2017 Financial Results and Demcizumab DENALI Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/13/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
OncoMed Pharma (OMED) Tops Q1 EPS by 2c
May 8, 2017 6:51 AM EDTOncoMed Pharma (NASDAQ: OMED) reported Q1 EPS of ($0.61), $0.02 better than the analyst estimate of ($0.63). Revenue for the quarter came in at $6.2 million versus the consensus estimate of $6.97 million.
2017 Financial Guidance OncoMed anticipates 2017 full-year cash expenses will be approximately $90 million, including the impact of... More
